My Intelligent Machines
Platform as a service helping biologists analyze genomic data.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $5.0m | Early VC | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 36 % | 43 % | - | (91 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
My Intelligent Machines (MIMs) is a Montreal-based leader in artificial intelligence and systems biology, specializing in personalized medicine. The company leverages AI and genomics to provide biopharma companies with easy-to-implement, interactive augmented intelligence systems. These systems facilitate accurate biological simulations during early drug development stages, assisting life scientists in developing precisely targeted and personalized therapies. MIMs' platform offers solutions for patient stratification, indication prioritization for clinical trials, target discovery, and biomarker discovery. The core AI of their software is a Goal-Oriented Massive Multiagent System (GOMMAS), which manages training of life scientists, automated machine learning model generation, data quality assessment, data analysis, and integration. The platform also captures, aggregates, curates, and updates knowledge from both structured and unstructured sources monthly. MIMs serves biopharma companies operating in the personalized medicine market, utilizing a B2B business model. The company generates revenue through software licensing and service fees for their AI-powered systems biology solutions.
Keywords: AI, genomics, personalized medicine, biopharma, systems biology, patient stratification, biomarker discovery, clinical trials, augmented intelligence, drug development.